ADMA's logo.
Ticker Symbol: ADMA

Adma Biologics Inc

$1.55 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001368514

Company Profile

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $3.16
Change: $0.01 ( 0.32%)
Days Range: $3.13 - $3.22
Beta: 1.53
52wk. High: $4.65
52wk. Low: $2.47
Ytd. Change -18.24%
50 Day Moving Average: $3.53
200 Day Moving Average: $3.74
Shares Outstanding: 224906426

Valuation

Market Cap: 71.1B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A